EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma

Silvia Pietrobono, Barbara Stecca

Oncotarget · 2023

DOI: 10.18632/oncotarget.28441 ↗

Kurz gefasst

Editorial in der Zeitschrift Oncotarget, 2023. Verfasst von Silvia Pietrobono und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Transcription Factors, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsMelanomaHumansHedgehog ProteinsNuclear ProteinsSignal TransductionZinc Finger Protein GLI1Cell Line, TumorCell ProliferationCell Cycle ProteinsBromodomain Containing Proteins

Stichwörter der Autor:innen

BRD4GLI1SOX2hedgehog signalingmelanoma

Substanzen

Transcription FactorsHedgehog ProteinsNuclear ProteinsZinc Finger Protein GLI1Cell Cycle ProteinsBRD4 protein, humanBromodomain Containing Proteins

Zitieren

APA

Pietrobono, S., & Stecca, B. (2023). Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma. Oncotarget. https://doi.org/10.18632/oncotarget.28441

Vancouver

Pietrobono S, Stecca B. Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma. Oncotarget. 2023. doi:10.18632/oncotarget.28441

BibTeX
@article{Pietrobono2023,
  author = {Pietrobono, Silvia and Stecca, Barbara},
  title = {Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma},
  journal = {Oncotarget},
  year = {2023},
  doi = {10.18632/oncotarget.28441}
}
Kostenlos starten →